Data / Form D filings / Oligomerix, Inc.
Oligomerix, Inc.: Form D filings
Oligomerix, Inc., a pharmaceuticals company in White Plains, NY, filed 5 Form D notices with the SEC between 2012 and 2024. The latest, on December 6, 2024, reports $75,000 sold of a $650,000 offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2 WESTCHESTER PARK DRIVE, SUITE 208, White Plains, NY, 10604
- Phone
- (212) 568-0365
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1543843
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 6, 2024 | New notice | $650,000 | $75,000 | $575,000 | 3 | Nov 25, 2024 | sec.gov |
| Mar 29, 2022 | New notice | $3,500,000 | $2,440,568 | $1,059,432 | 12 | Mar 24, 2022 | sec.gov |
| Apr 15, 2015 | New notice | $3,000,000 | $400,000 | $2,600,000 | 2 | Apr 3, 2015 | sec.gov |
| Feb 14, 2013 | New notice | $2,800,000 | $0 | $2,800,000 | 0 | Yet to occur | sec.gov |
| Mar 20, 2012 | New notice | $2,700,000 | $0 | $2,700,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Douglas Durand | Director | |
| William Erhardt | Executive Officer, Director | |
| Robert Foerster | Executive Officer, Director | |
| Jeffrey Bluestein | Director | |
| Eliot Davidowitz | Executive Officer, Director | |
| James Moe | Executive Officer, Director | |
| David Dantzker | Director | |
| Jack Pasini | Executive Officer, Director |
Other pharmaceuticals companies in New York that filed recently
- Pierrepont Therapeutics, Inc. $2.4 million · Sep 22, 2026
Every Form D from the week of Dec 2, 2024 · All recent filings in New York · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Oligomerix, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.